Thomas Bachelot, MD, PhD, Centre Leon Berard

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.

Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.

Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.

An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.

Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.